Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency

Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency

Metastatic dissemination in breast cancer patients occurs early in malignant transformation, raising questions about how disseminated cancer cells (DCC) progress at distant sites. Here, the authors show that DCCs in bone marrow are activated via IL6-trans-signaling and thereby acquire stemness trait...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Melanie Werner-Klein, Ana Grujovic, Christoph Irlbeck, Milan Obradović, Martin Hoffmann, Huiqin Koerkel-Qu, Xin Lu, Steffi Treitschke, Cäcilia Köstler, Catherine Botteron, Kathrin Weidele, Christian Werno, Bernhard Polzer, Stefan Kirsch, Miodrag Gužvić, Jens Warfsmann, Kamran Honarnejad, Zbigniew Czyz, Giancarlo Feliciello, Isabell Blochberger, Sandra Grunewald, Elisabeth Schneider, Gundula Haunschild, Nina Patwary, Severin Guetter, Sandra Huber, Brigitte Rack, Nadia Harbeck, Stefan Buchholz, Petra Rümmele, Norbert Heine, Stefan Rose-John, Christoph A. Klein
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/852fb79d2cfa456b923be4f3ce115b15
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:852fb79d2cfa456b923be4f3ce115b15
record_format dspace
spelling oai:doaj.org-article:852fb79d2cfa456b923be4f3ce115b152021-12-02T17:13:19ZInterleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency10.1038/s41467-020-18701-42041-1723https://doaj.org/article/852fb79d2cfa456b923be4f3ce115b152020-10-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-18701-4https://doaj.org/toc/2041-1723Metastatic dissemination in breast cancer patients occurs early in malignant transformation, raising questions about how disseminated cancer cells (DCC) progress at distant sites. Here, the authors show that DCCs in bone marrow are activated via IL6-trans-signaling and thereby acquire stemness traits relevant for metastasis formation.Melanie Werner-KleinAna GrujovicChristoph IrlbeckMilan ObradovićMartin HoffmannHuiqin Koerkel-QuXin LuSteffi TreitschkeCäcilia KöstlerCatherine BotteronKathrin WeideleChristian WernoBernhard PolzerStefan KirschMiodrag GužvićJens WarfsmannKamran HonarnejadZbigniew CzyzGiancarlo FelicielloIsabell BlochbergerSandra GrunewaldElisabeth SchneiderGundula HaunschildNina PatwarySeverin GuetterSandra HuberBrigitte RackNadia HarbeckStefan BuchholzPetra RümmeleNorbert HeineStefan Rose-JohnChristoph A. KleinNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-18 (2020)
institution DOAJ
collection DOAJ
language EN
topic Science
Q
spellingShingle Science
Q
Melanie Werner-Klein
Ana Grujovic
Christoph Irlbeck
Milan Obradović
Martin Hoffmann
Huiqin Koerkel-Qu
Xin Lu
Steffi Treitschke
Cäcilia Köstler
Catherine Botteron
Kathrin Weidele
Christian Werno
Bernhard Polzer
Stefan Kirsch
Miodrag Gužvić
Jens Warfsmann
Kamran Honarnejad
Zbigniew Czyz
Giancarlo Feliciello
Isabell Blochberger
Sandra Grunewald
Elisabeth Schneider
Gundula Haunschild
Nina Patwary
Severin Guetter
Sandra Huber
Brigitte Rack
Nadia Harbeck
Stefan Buchholz
Petra Rümmele
Norbert Heine
Stefan Rose-John
Christoph A. Klein
Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency
description Metastatic dissemination in breast cancer patients occurs early in malignant transformation, raising questions about how disseminated cancer cells (DCC) progress at distant sites. Here, the authors show that DCCs in bone marrow are activated via IL6-trans-signaling and thereby acquire stemness traits relevant for metastasis formation.
format article
author Melanie Werner-Klein
Ana Grujovic
Christoph Irlbeck
Milan Obradović
Martin Hoffmann
Huiqin Koerkel-Qu
Xin Lu
Steffi Treitschke
Cäcilia Köstler
Catherine Botteron
Kathrin Weidele
Christian Werno
Bernhard Polzer
Stefan Kirsch
Miodrag Gužvić
Jens Warfsmann
Kamran Honarnejad
Zbigniew Czyz
Giancarlo Feliciello
Isabell Blochberger
Sandra Grunewald
Elisabeth Schneider
Gundula Haunschild
Nina Patwary
Severin Guetter
Sandra Huber
Brigitte Rack
Nadia Harbeck
Stefan Buchholz
Petra Rümmele
Norbert Heine
Stefan Rose-John
Christoph A. Klein
author_facet Melanie Werner-Klein
Ana Grujovic
Christoph Irlbeck
Milan Obradović
Martin Hoffmann
Huiqin Koerkel-Qu
Xin Lu
Steffi Treitschke
Cäcilia Köstler
Catherine Botteron
Kathrin Weidele
Christian Werno
Bernhard Polzer
Stefan Kirsch
Miodrag Gužvić
Jens Warfsmann
Kamran Honarnejad
Zbigniew Czyz
Giancarlo Feliciello
Isabell Blochberger
Sandra Grunewald
Elisabeth Schneider
Gundula Haunschild
Nina Patwary
Severin Guetter
Sandra Huber
Brigitte Rack
Nadia Harbeck
Stefan Buchholz
Petra Rümmele
Norbert Heine
Stefan Rose-John
Christoph A. Klein
author_sort Melanie Werner-Klein
title Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency
title_short Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency
title_full Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency
title_fullStr Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency
title_full_unstemmed Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency
title_sort interleukin-6 trans-signaling is a candidate mechanism to drive progression of human dccs during clinical latency
publisher Nature Portfolio
publishDate 2020
url https://doaj.org/article/852fb79d2cfa456b923be4f3ce115b15
work_keys_str_mv AT melaniewernerklein interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT anagrujovic interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT christophirlbeck interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT milanobradovic interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT martinhoffmann interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT huiqinkoerkelqu interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT xinlu interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT steffitreitschke interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT caciliakostler interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT catherinebotteron interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT kathrinweidele interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT christianwerno interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT bernhardpolzer interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT stefankirsch interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT miodragguzvic interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT jenswarfsmann interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT kamranhonarnejad interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT zbigniewczyz interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT giancarlofeliciello interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT isabellblochberger interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT sandragrunewald interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT elisabethschneider interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT gundulahaunschild interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT ninapatwary interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT severinguetter interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT sandrahuber interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT brigitterack interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT nadiaharbeck interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT stefanbuchholz interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT petrarummele interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT norbertheine interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT stefanrosejohn interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
AT christophaklein interleukin6transsignalingisacandidatemechanismtodriveprogressionofhumandccsduringclinicallatency
_version_ 1718381328887447552

Ejemplares similares